Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California, USA.
J Am Coll Cardiol. 2021 Apr 13;77(14):1813-1822. doi: 10.1016/j.jacc.2021.01.056.
The prevalence of cardiovascular disease (CVD) in pregnancy, both diagnosed and previously unknown, is rising, and CVD is a leading cause of maternal morbidity and mortality. Historically, women of child-bearing potential have been underrepresented in research, leading to lasting knowledge gaps in the cardiovascular care of pregnant and lactating women. Despite these limitations, clinicians should be familiar with the safety of frequently used diagnostic and therapeutic interventions to adequately care for this at-risk population. This review, the fourth of a 5-part series, provides evidence-based recommendations regarding the use of common cardiovascular diagnostic tests and medications in pregnant and lactating women.
妊娠合并心血管疾病(CVD)的患病率不断上升,包括已诊断和先前未知的 CVD,CVD 是导致孕产妇发病率和死亡率的主要原因。从历史上看,生育期女性在研究中代表性不足,导致在妊娠和哺乳期女性心血管护理方面存在持久的知识空白。尽管存在这些局限性,临床医生仍应熟悉常用诊断和治疗干预措施的安全性,以充分照顾这一高危人群。本综述是 5 部分系列中的第 4 部分,提供了关于在妊娠和哺乳期女性中使用常见心血管诊断测试和药物的基于证据的建议。